This topic contains a solution. Click here to go to the answer

Author Question: The marginal propensity to consume describes ________. A) the tendency to consume fringe, or ... (Read 88 times)

kshipps

  • Hero Member
  • *****
  • Posts: 571
The marginal propensity to consume describes ________.
 
  A) the tendency to consume fringe, or unusual items
  B) the impact of a change in spending on income
  C) the impact on consumption resulting from a change in income
  D) lifetime consumption resources

Question 2

If the public believes that the commitment to a nominal anchor is not credible, the effect of a positive aggregate demand shock is for ________.
 
  A) short-run aggregate supply to shift down
  B) short-run aggregate supply to remain unchanged
  C) short-run aggregate supply to shift up
  D) inflation, but not economic activity, to increase



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

karlss

  • Sr. Member
  • ****
  • Posts: 321
Answer to Question 1

C

Answer to Question 2

C




kshipps

  • Member
  • Posts: 571
Reply 2 on: Jun 30, 2018
Wow, this really help


bassamabas

  • Member
  • Posts: 294
Reply 3 on: Yesterday
YES! Correct, THANKS for helping me on my review

 

Did you know?

Though Candida and Aspergillus species are the most common fungal pathogens causing invasive fungal disease in the immunocompromised, infections due to previously uncommon hyaline and dematiaceous filamentous fungi are occurring more often today. Rare fungal infections, once accurately diagnosed, may require surgical debridement, immunotherapy, and newer antifungals used singly or in combination with older antifungals, on a case-by-case basis.

Did you know?

Thyroid conditions may make getting pregnant impossible.

Did you know?

Vaccines prevent between 2.5 and 4 million deaths every year.

Did you know?

It is difficult to obtain enough calcium without consuming milk or other dairy foods.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library